HTG Molecular Diagnostics Completes Module Three Filing for HTG EdgeSeq ALKPlus Assay PMA
TUCSON, Ariz., Jan. 05, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments and reagents for molecular profiling applications, today announced that it has submitted to the FDA the third of four expected modules for the Company’s Pre-Market Approval (PMA) application for the HTG EdgeSeq ALKPlus Assay to be used as a companion diagnostic for Crizotinib.